Navigate the Next Growth Frontiers in Clinical Diagnostics
Building a smarter, more integrated healthcare ecosystem
Download the Full Analysis
The clinical diagnostics industry is changing as demand increases for molecular diagnostics, tissue diagnostics, point-of-care testing (POCT), and integrated chemistry-immunoassay systems. Healthcare providers are looking for faster testing, better workflow management, and broader access to diagnostic services.
At the same time, routine centralized testing is growing at a slower pace due to automation maturity and reimbursement pressure, while specialty molecular testing, precision oncology, and decentralized diagnostics are generating stronger growth opportunities.
Our latest analysis looks at how diagnostics vendors, laboratories, and healthcare providers are adapting to the above changes through decentralized molecular workflows, digital pathology, automation, and connected testing systems.
Are you positioned to lead as diagnostics evolves from a testing function into an integrated clinical intelligence layer?
What You’ll Find in Frost & Sullivan’s Latest Analysis:
Technology best practices
The shift from standalone instruments to interconnected ecosystems including microfluidic polymerase chain reaction (PCR), next-generation sequencing (NGS) automation, digital pathology, and cloud-native informatics.
Partnership and vendor strategies
What separates full-stack diagnostics partners, combining automation, analytics, and connectivity—from traditional reagent and equipment manufacturers.
Regional megatrends
North America's digital adoption scaling, In Vitro Diagnostic Regulation (IVDR) reshaping European market entry, and APAC's decentralization push creating new volume growth opportunities.